MCL1 and acute lymphoblastic leukemia: Blast cells were treated with 10μM imatinib, 500μM ribavirin, and combination for 48h, and the results suggested that ribavirin alone significantly reduced the phosphorylation of mTOR/eIF4E, ERK/Mnk1/eIF4E signaling pathways, substrates Mcl-1, and p-Lyn in all 6 cases of Ph+ ALL primary blasts, and the combination of ribavirin and imatinib had greater effect on the signaling pathways, as described in the cell lines (Fig 6B and 6C).